Compare IDEXX Laboratories, Inc. (IDXX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Merck & Co., Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518.89 (market cap $40.43B), while Merck & Co., Inc. trades at $146 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 8.7× IDEXX Laboratories, Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Merck & Co., Inc. for 98 Days on average.
| IDXX | MRK | |
|---|---|---|
Market Cap | $40.43B | $351.28B |
Volume | 692,164 | 7,969,665 |
Sector | Health | Health |
52-Week High | $766.68 | $156.43 |
52-Week Low | $504.70 | $82.49 |
Typical Hold Time | 46 Days | 98 Days |
Enterprise Value | $41.32B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
